Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
November 13, 2019 08:01 ET
|
Allena Pharmaceuticals, Inc.
-- Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial of Reloxaliase in Enteric Hyperoxaluria (EH), with Statistically Significant Reduction in Urinary Oxalate (UOx) Compared to...
Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206
November 07, 2019 06:55 ET
|
Allena Pharmaceuticals, Inc.
Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria Phase 2 Study 206 Trial Demonstrates Substantial...
Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting
October 17, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria
September 16, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,...
Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase
September 11, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,...
Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September
August 29, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
August 07, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Interim Data from Study 206 Demonstrated Substantial Treatment Effect in Patients with Enteric Hyperoxaluria and Advanced Chronic Kidney Disease, Including Robust Reductions in Both Urine and...
Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
August 06, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock
June 27, 2019 20:45 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Program at OHF International Hyperoxaluria Workshop
June 21, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., June 21, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...